Soleno Therapeutics, Inc. (SLNO)
NASDAQ: SLNO · Real-Time Price · USD
54.63
-0.20 (-0.36%)
Nov 21, 2024, 4:00 PM EST - Market closed

Company Description

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.

Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.

The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017.

Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Soleno Therapeutics, Inc.
Soleno Therapeutics logo
Country United States
Founded 1999
IPO Date Nov 13, 2014
Industry Biotechnology
Sector Healthcare
Employees 33
CEO Anish Bhatnagar

Contact Details

Address:
203 Redwood Shores Parkway, Suite 500
Redwood City, California 94065
United States
Phone 650 213 8444
Website soleno.life

Stock Details

Ticker Symbol SLNO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001484565
CUSIP Number 834203200
ISIN Number US8342033094
Employer ID 77-0523891
SIC Code 3845

Key Executives

Name Position
Dr. Anish Bhatnagar M.D. President, Chief Executive Officer, Chief Operating Officer and Director
James H. MacKaness Chief Financial Officer
Patricia C. Hirano M.P.H. Senior Vice President of Regulatory Affairs
Lauren Budesheim Vice President of People
Kristen Yen M.S. Senior Vice President of Clinical Operations
Dr. Neil M. Cowen M.B.A., Ph.D. Senior Vice President of Drug Development
Meredith Manning M.B.A. Chief Commercial Officer
Dr. Michael Huang M.D. Senior Vice President of Clinical Development
Dr. Raymond W. Urbanski M.D., Ph.D. Chief Development Officer
Dr. Mitchell Nagao M.B.A., Pharm.D. Senior Vice President of Medical Affairs

Latest SEC Filings

Date Type Title
Nov 19, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Nov 14, 2024 SCHEDULE 13G/A Filing
Nov 14, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 6, 2024 8-K Current Report
Nov 6, 2024 10-Q Quarterly Report
Oct 24, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Oct 21, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership